Prostate Cancer vs Colorectal Cancer — Clinical Trial Comparison
Prostate Cancer
Most common cancer in UK men
VS
Colorectal Cancer
Third most common cancer in the UK
Prostate cancer and colorectal cancer are two of the most common cancers in the UK, together accounting for nearly 80,000 new diagnoses each year. While both benefit from screening and have expanding treatment options, their trial landscapes differ significantly. Prostate cancer trials increasingly focus on advanced disease and precision approaches, while colorectal cancer trials span prevention, early detection, and novel treatments.
Key Differences at a Glance
| Feature | Prostate Cancer | Colorectal Cancer |
|---|---|---|
| UK cases per year | ~52,000 | ~43,000 |
| Key biomarkers | PSA, Gleason score, BRCA2, HRD, AR mutations, PTEN | CEA, MSI/MMR, KRAS, BRAF, RAS, HER2, NTRK |
| Screening available | PSA testing (controversial, not national programme) | NHS Bowel Cancer Screening (FIT test, age 54-74) |
| Common subtypes | Localised, locally advanced, metastatic, castration-resistant | Colon, rectal, MSI-H, MSS, left-sided, right-sided |
| 5-year survival | ~87% (all stages) | ~60% (all stages) |
| NICE first-line (advanced) | ADT + ARPI (abiraterone, enzalutamide) | FOLFOX/FOLFIRI + targeted therapy based on biomarkers |
Clinical Trial Availability
| Trial Aspect | Prostate Cancer | Colorectal Cancer |
|---|---|---|
| UK trials actively recruiting | 80-130 studies | 60-100 studies |
| Most common trial phase | Phase 2-3 | Phase 2-3 |
| Top drug classes tested | ARPIs, PARP inhibitors, radioligand therapy (Lu-PSMA), immunotherapy, bispecifics | Immunotherapy, targeted therapy (anti-EGFR, anti-VEGF), novel chemo, CAR-T, tumour-agnostic |
| Biomarker-driven trials | Major focus (BRCA/HRD, MSI, AR mutations) | Major focus (MSI/MMR, RAS, BRAF, HER2, NTRK) |
| Prevention trials | Limited | Active (aspirin, diet, chemoprevention in high-risk) |
| Surgery-focused trials | Active (robotic prostatectomy, focal therapy) | Active (TME, robotic surgery, organ preservation) |
Exciting Emerging Treatments
Prostate Cancer Trials
- Radioligand therapy (Lu-PSMA-617) — targeted radiation to PSMA-expressing cells
- PARP inhibitor combinations — for BRCA/HRD-mutant and broader populations
- Bispecific antibodies — engaging immune cells against prostate cancer
- AR degraders (PROTACs) — destroying androgen receptor rather than blocking
- Focal therapy trials — HIFU, cryotherapy, electroporation for localised disease
- Combination hormone therapy — triple androgen deprivation approaches
Colorectal Cancer Trials
- Immunotherapy combinations — checkpoint inhibitors for MSI-H and novel combos for MSS
- Antibody-drug conjugates — targeting tumour-specific antigens in CRC
- Circulating tumour DNA (ctDNA) — guiding adjuvant therapy decisions
- TRK inhibitors — for NTRK fusion-positive tumours (tumour-agnostic)
- Organ preservation trials — avoiding surgery in rectal cancer responders
- Gut microbiome modulation — enhancing immunotherapy response
💡 Not sure which trials you qualify for?
Use our Smart Matcher to answer a few questions about your condition and we'll find the most relevant trials for your specific situation — free, instant results.
Eligibility Differences
Prostate Cancer Trial Criteria
- PSA level and Gleason score determine staging and trial eligibility
- Castration-resistant (CRPC) trials require documented progression on ADT
- Metastatic trials require imaging-confirmed distant disease
- BRCA/HRD testing increasingly required for PARP inhibitor trials
- Prior ARPI exposure often specified (abiraterone and/or enzalutamide)
Colorectal Cancer Trial Criteria
- Tumour sidedness (left vs right colon) increasingly determines trial eligibility
- RAS/BRAF mutation status critical for anti-EGFR trial eligibility
- MSI/MMR status determines immunotherapy trial suitability
- CEA levels tracked as biomarker for trial inclusion and response
- Prior lines of therapy specified (treatment-naive vs refractory)
Prostate Cancer Trials
Find actively recruiting prostate cancer trials across the UK
Prostate Cancer TrialsColorectal Cancer Trials
Find actively recruiting colorectal cancer trials across the UK
Colorectal Cancer TrialsFrequently Asked Questions
Can I join a clinical trial if I have both Prostate Cancer and Colorectal Cancer?
It depends on the specific trial. Many trials allow comorbid conditions as long as the primary condition being studied is clearly dominant. Some trials explicitly exclude patients with significant overlapping conditions. Always check the eligibility criteria carefully and discuss with both the trial team and your specialist.
Which condition has more clinical trials available in the UK?
Both Prostate Cancer and Colorectal Cancer have robust research pipelines with new studies opening regularly. The number of trials varies over time as new studies launch and others complete. Check our condition pages for the most current trial availability.
What should I consider when choosing between trials for these conditions?
Consider which condition impacts your quality of life most, what treatments you've already tried, the trial phase (earlier phases are more experimental), the time commitment involved, and whether the trial offers access to treatments not otherwise available. Your specialist can help you prioritise.